drugset / Trial / NCT00148668
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
Phase 2
Completed
81 enrolled
Eric Winer, MD
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabDana-Farber Cancer Institute · collabMassachusetts General Hospital · collabYale University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 positive breast cancer.
Timeline
- Start
- 2003-12
- Primary completion
- 2009-01
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |
| Comparator | Vinorelbine | Small molecule | — | — |